Estrogen receptor beta in breast cancer

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 665-672

  Haldosén, Lars Arne ^a   Zhao, Chunyan ^a   Dahlman Wright, Karin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Breast cancer; Breast cancer marker; ERbeta isoforms; Estrogen receptor beta

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA AGONIST; ESTROGEN RECEPTOR BETA ANTIBODY; TRANSCRIPTOME; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; BREAST METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CORRELATION ANALYSIS; DISEASE MODEL; EPIGENETICS; ESR2 GENE; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR INVASION; VALIDATION STUDY;

BREAST CANCER; BREAST CANCER MARKER; ERBETA ISOFORMS; ESTROGEN RECEPTOR BETA;

BREAST; BREAST NEOPLASMS; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84888368660     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.08.005     Document Type: Review

References (60)

1. Bozkurt K.K., Kapucuoglu N. Investigation of immunohistochemical ERalpha, ERbeta and ERbetacx expressions in normal and neoplastic breast tissues. Pathol. Res. Pract. 2012, 208:133-139.
2. Carder P.J., Murphy C.E., Dervan P., Kennedy M., McCann A., Saunders P.T., Shaaban A.M., Foster C.S., Witton C.J., Bartlett J.M., Walker R.A., Speirs V. A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res. Treat. 2005, 92:287-293.
3. Chang E.C., Frasor J., Komm B., Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006, 147:4831-4842.
4. Charn T.H., Liu E.T., Chang E.C., Lee Y.K., Katzenellenbogen J.A., Katzenellenbogen B.S. Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol. Endocrinol. 2010, 24:47-59.
5. Dey P., Jonsson P., Hartman J., Williams C., Strom A., Gustafsson J.A. Estrogen receptors beta 1 and beta 2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol. Endocrinol. 2012, 26:1991-2003.
6. Duong V., Licznar A., Margueron R., Boulle N., Busson M., Lacroix M., Katzenellenbogen B.S., Cavailles V., Lazennec G. ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2006, 25:1799-1806.
7. Esslimani-Sahla M., Simony-Lafontaine J., Kramar A., Lavaill R., Mollevi C., Warner M., Gustafsson J.A., Rochefort H. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res. 2004, 10:5769-5776.
8. Forster C., Makela S., Warri A., Kietz S., Becker D., Hultenby K., Warner M., Gustafsson J.A. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA 2002, 99:15578-15583.
9. Fuqua S.A., Schiff R., Parra I., Moore J.T., Mohsin S.K., Osborne C.K., Clark G.M., Allred D.C. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003, 63:2434-2439.
10. Gruvberger-Saal S.K., Bendahl P.O., Saal L.H., Laakso M., Hegardt C., Eden P., Peterson C., Malmstrom P., Isola J., Borg A., Ferno M. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin. Cancer Res. 2007, 13:1987-1994.
11. Hartman J., Lindberg K., Morani A., Inzunza J., Strom A., Gustafsson J.A. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006, 66:11207-11213.
12. Hartman J., Edvardsson K., Lindberg K., Zhao C., Williams C., Strom A., Gustafsson J.A. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res. 2009, 69:6100-6106.
13. Helguero L.A., Faulds M.H., Gustafsson J.A., Haldosen L.A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005, 24:6605-6616.
14. Hirata S., Shoda T., Kato J., Hoshi K. The multiple untranslated first exons system of the human estrogen receptor beta (ER beta) gene. J. Steroid. Biochem. Mol. Biol. 2001, 78:33-40.
15. Hodges-Gallagher L., Valentine C.D., Bader S.E., Kushner P.J. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res. Treat. 2007, 105:297-309.
16. Hodges-Gallagher L., Valentine C.D., El Bader S., Kushner P.J. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res. Treat. 2008, 109:241-250.
17. Honma N., Horii R., Iwase T., Saji S., Younes M., Takubo K., Matsuura M., Ito Y., Akiyama F., Sakamoto G. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol. 2008, 26:3727-3734.
18. Honma N., Saji S., Kurabayashi R., Aida J., Arai T., Horii R., Akiyama F., Iwase T., Harada N., Younes M., Toi M., Takubo K., Sakamoto G. Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. Apmis 2008, 116:923-930.
19. Huang J.H., Zhang J., Zager E.L. Diagnosis and treatment options for nerve sheath tumors. Expert Rev. Neurother. 2005, 5:515-523.
20. Jang E.R., Lim S.J., Lee E.S., Jeong G., Kim T.Y., Bang Y.J., Lee J.S. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 2004, 23:1724-1736.
21. Leung Y.K., Mak P., Hassan S., Ho S.M. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc. Natl. Acad. Sci. USA 2006, 103:13162-13167.
22. Leygue E., Murphy L.C. A bi-faceted role of estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 2013.
23. Lippman M., Bolan G., Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1976, 36:4595-4601.
24. Liu Y., Gao H., Marstrand T.T., Strom A., Valen E., Sandelin A., Gustafsson J.A., Dahlman-Wright K. The genome landscape of ERalpha- and ERbeta-binding DNA regions. Proc. Natl. Acad. Sci. USA 2008, 105:2604-2609.
25. Marotti J.D., Collins L.C., Hu R., Tamimi R.M. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod. Pathol. 2010, 23:197-204.
26. Matthews J., Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv. 2003, 3:281-292.
27. Miller W.R., Anderson T.J., Dixon J.M., Saunders P.T. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br. J. Cancer 2006, 94:1333-1338.
28. Moore J.T., McKee D.D., Slentz-Kesler K., Moore L.B., Jones S.A., Horne E.L., Su J.L., Kliewer S.A., Lehmann J.M., Willson T.M. Cloning and characterization of human estrogen receptor beta isoforms. Biochem. Biophys. Res. Commun. 1998, 247:75-78.
29. Myers E., Fleming F.J., Crotty T.B., Kelly G., McDermott E.W., O'Higgins N.J., Hill A.D., Young L.S. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br. J. Cancer 2004, 91:1687-1693.
30. Nakopoulou L., Lazaris A.C., Panayotopoulou E.G., Giannopoulou I., Givalos N., Markaki S., Keramopoulos A. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J. Clin. Pathol. 2004, 57:523-528.
31. Novelli F., Milella M., Melucci E., Di Benedetto A., Sperduti I., Perrone-Donnorso R., Perracchio L., Venturo I., Nistico C., Fabi A., Buglioni S., Natali P.G., Mottolese M. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 2008, 10:R74.
32. Ogawa S., Inoue S., Watanabe T., Hiroi H., Orimo A., Hosoi T., Ouchi Y., Muramatsu M. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem. Biophys. Res. Commun. 1998, 243:122-126.
33. Ogawa S., Inoue S., Watanabe T., Orimo A., Hosoi T., Ouchi Y., Muramatsu M. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res. 1998, 26:3505-3512.
34. Omoto Y., Kobayashi S., Inoue S., Ogawa S., Toyama T., Yamashita H., Muramatsu M., Gustafsson J.A., Iwase H. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur. J. Cancer 2002, 38:380-386.
35. Palmieri C., Cheng G.J., Saji S., Zelada-Hedman M., Warri A., Weihua Z., Van Noorden S., Wahlstrom T., Coombes R.C., Warner M., Gustafsson J.A. Estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 2002, 9:1-13.
36. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
37. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004, 64:423-428.
38. Putnik M., Zhao C., Gustafsson J.A., Dahlman-Wright K. Effects of two common polymorphisms in the 3' untranslated regions of estrogen receptor beta on mRNA stability and translatability. BMC Genet. 2009, 10:55.
39. Rody A., Holtrich U., Solbach C., Kourtis K., von Minckwitz G., Engels K., Kissler S., Gatje R., Karn T., Kaufmann M. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr. Relat. Cancer 2005, 12:903-916.
40. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001, 61:2537-2541.
41. Sawyers C.L. The cancer biomarker problem. Nature 2008, 452:548-552.
42. Secreto F.J., Monroe D.G., Dutta S., Ingle J.N., Spelsberg T.C. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J. Cell. Biochem. 2007, 101:1125-1147.
43. Shaaban A.M., Green A.R., Karthik S., Alizadeh Y., Hughes T.A., Harkins L., Ellis I.O., Robertson J.F., Paish E.C., Saunders P.T., Groome N.P., Speirs V. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin. Cancer Res. 2008, 14:5228-5235.
44. Skliris G.P., Parkes A.T., Limer J.L., Burdall S.E., Carder P.J., Speirs V. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J. Pathol. 2002, 197:155-162.
45. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lonning P.E., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
46. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100:8418-8423.
47. Sotoca A.M., van den Berg H., Vervoort J., van der Saag P., Strom A., Gustafsson J.A., Rietjens I., Murk A.J. Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol. Sci. 2008, 105:303-311.
48. Speirs V., Skliris G.P., Burdall S.E., Carder P.J. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J. Clin. Pathol. 2002, 55:371-374.
49. Strom A., Hartman J., Foster J.S., Kietz S., Wimalasena J., Gustafsson J.A. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA 2004, 101:1566-1571.
50. Sugiura H., Toyama T., Hara Y., Zhang Z., Kobayashi S., Fujii Y., Iwase H., Yamashita H. Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn. J. Clin. Oncol. 2007, 37:820-828.
51. Tate C.R., Rhodes L.V., Segar H.C., Driver J.L., Pounder F.N., Burow M.E., Collins-Burow B.M. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012, 14:R79.
52. Thomas C., Rajapaksa G., Nikolos F., Hao R., Katchy A., McCollum C.W., Bondesson M., Quinlan P., Thompson A., Krishnamurthy S., Esteva F.J., Gustafsson J.A. ERbeta1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012, 14:R148.
53. Vinayagam R., Sibson D.R., Holcombe C., Aachi V., Davies M.P. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer - a retrospective study. BMC Cancer 2007, 7:131.
54. Williams C., Edvardsson K., Lewandowski S.A., Strom A., Gustafsson J.A. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 2008, 27:1019-1032.
55. Wurster M., Ruoff A., Meisner C., Seeger H., Vogel U., Juhasz-Boss I., Solomayer E., Wallwiener D., Fehm T., Neubauer H. Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer. Oncol. Rep. 2010, 24:653-659.
56. Yan M., Rayoo M., Takano E.A., Fox S.B. Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res. Treat. 2011, 126:395-405.
57. Yu K.D., Rao N.Y., Chen A.X., Fan L., Yang C., Shao Z.M. A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. Breast Cancer Res. Treat. 2011, 126:37-45.
58. Zhang H., Zhang Z., Xuan L., Zheng S., Guo L., Zhan Q., Qu X., Zhang B., Wang Y., Wang X., Song Y. Evaluation of ER-alpha, ER-Beta1 and ER-Beta2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers. Clin. Transl. Oncol. 2012, 14:225-231.
59. Zhao C., Lam E.W., Sunters A., Enmark E., De Bella M.T., Coombes R.C., Gustafsson J.A., Dahlman-Wright K. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003, 22:7600-7606.
60. Zhao C., Matthews J., Tujague M., Wan J., Strom A., Toresson G., Lam E.W., Cheng G., Gustafsson J.A., Dahlman-Wright K. Estrogen receptor beta 2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res. 2007, 67:3955-3962.